Day One Biopharmaceuticals pany(US:DAWN)2025-11-04 21:00Revenue Performance - OJEMDA net product revenue reached $38.5 million in Q3 2025, a 15% increase from Q2 2025[3] - Year-to-date U.S. OJEMDA net product revenue totaled $102.6 million, representing an 89% increase over FY 2024[3] - Quarterly prescriptions (TRx) for OJEMDA grew to 1,256, an 18% increase compared to Q2 2025[3] - New patient starts increased by 19% in Q3 2025, driven by the FIREFLY-1 clinical trial data[3] - The company raised its full-year 2025 net product revenue guidance for OJEMDA to $145 to $150 million[3] - Total revenues for Q3 2025 were $39.8 million, compared to $93.8 million in Q3 2024, which included a one-time license revenue of $73.7 million[9] Expenses - Research and development expenses were $31.4 million in Q3 2025, down from $33.6 million in Q3 2024[9] - Selling, general and administrative expenses decreased to $28.1 million in Q3 2025 from $29.0 million in Q3 2024[9] Financial Position - The net loss for Q3 2025 was $19.7 million, compared to a net income of $37.0 million in Q3 2024[9] - As of September 30, 2025, the company had $451.6 million in cash, cash equivalents, and short-term investments[9]